Advances in the Study of Inhaled Formulations for the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a serious disease with reduced systemic circulation and low bioavailability associated with conventional and dosed therapy, which inhaled drugs can avoid. A mean pulmonary artery pressure (mPAP) of ≥25 mmHg (1 mmHg = 0.133 kPa) at rest or ≥30 mmHg during exer...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Fei, Chen, Yongqi, Li, Shijie, Yang, Yankun, Bai, Zhonghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184198/
https://www.ncbi.nlm.nih.gov/pubmed/35694279
http://dx.doi.org/10.1155/2022/6495645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184198/
https://www.ncbi.nlm.nih.gov/pubmed/35694279
http://dx.doi.org/10.1155/2022/6495645

Ejemplares similares